Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLQ | O75417 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.37 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6867247 | 1.00 | HSP90AB1 (0.38) | HSP90AB1LMNAPOLQALBHSP90AA1 | |
| SCHEMBL6943889 | 0.87 | HSP90AB1 (0.43) | HSP90AB1LMNAPOLQALBHSP90AA1 | |
| SCHEMBL6943894 | 0.87 | HSP90AB1 (0.43) | HSP90AB1LMNAPOLQALBHSP90AA1 | |
| SCHEMBL6860305 | 0.87 | HSP90AB1 (0.45) | HSP90AB1LMNAPOLQALBHSP90AA1 | |
| SCHEMBL6860302 | 0.87 | HSP90AB1 (0.45) | HSP90AB1LMNAPOLQALBHSP90AA1 | |
| SCHEMBL7789936 | 0.86 | — | — | |
| SCHEMBL6940657 | 0.85 | LMNA (0.44) | HSP90AB1LMNAPOLQALBHSP90AA1 | |
| SCHEMBL6941760 | 0.85 | LMNA (0.44) | HSP90AB1LMNAPOLQALBHSP90AA1 | |
| SCHEMBL7074596 | 0.84 | LMNA (0.45) | HSP90AB1LMNAPOLQALBHSP90AA1 | |
| SCHEMBL7075739 | 0.84 | LMNA (0.45) | HSP90AB1LMNAPOLQALBHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812331-B2 | BACTERICIDES | AVENTIS PHARMA S.A. (FR) | 2004-11-02 | — | — | US | disclosed |
| US-6350733-B1 | 4-HYDROXYBENZOPYRAN-2-ONE DERIVATIVES; BACTERICIDES FOR STAPHYLOCOCCUS INFECTIONS; SKIN DISORDERS | AVENTIS PHARMA S.A. (FR) | 2002-02-26 | — | — | US | disclosed |
| US-20020010322-A1 | New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments | AVENTIS PHARMA S.A. | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010322-A1 | New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments | RPIA, CD38, PARP1 | HSP90AB1 1949/4885LMNA 1772/4885POLQ 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.